Detalhe da pesquisa
1.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Cancer
; 130(2): 287-299, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801052
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
3.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012435
4.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692409
5.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
6.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354090
7.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Am J Hematol
; 98(11): 1762-1771, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647134
8.
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
Chemotherapy
; 68(3): 131-137, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36549287
9.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
10.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
11.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
12.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31877211
13.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Am J Hematol
; 97(11): 1419-1426, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054756
14.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
15.
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol
; 193(2): 271-279, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403687
16.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
17.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
18.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388860
19.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499575
20.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137